B7-H3×ITGB6 bsADC (BeOne)

B7-H3×ITGB6双抗ADC (百济神州)

Report date: 2026/05/18 20:02:07

Base Information

Drug NameB7-H3×ITGB6 bsADC (BeOne)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-ITGB6Anti-CD276

TargetsIntegrin beta-6CD276 antigen

Therapy Area/IndicationsLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesBeOne Medicines Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines Ltd

Inactive CompaniesN/A

Active IndicationsLung Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A